TRex Bio

South San Francisco, United States

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

$84.0M raised

Nov 2024

Series B

Top Investors

Eli LillySV Health InvestorsPolaris PartnersAgent CapitalAlexandria Venture Investments

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has TRex Bio raised?

TRex Bio has raised $84.0M in total funding. The most recent round was Series B. The last funding was announced in November 2024.

Who are TRex Bio's investors?

TRex Bio's investors include Eli Lilly, SV Health Investors, Polaris Partners, Agent Capital, Alexandria Venture Investments.

Where is TRex Bio headquartered?

TRex Bio is headquartered in South San Francisco, United States.

What does TRex Bio do?

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

What stage is TRex Bio at?

TRex Bio is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated November 13, 2024.

MLA

"TRex Bio — Funding & Investors." VCBacked, November 13, 2024, https://www.vcbacked.co/company/trex-bio. Accessed June 14, 2026.

APA

VCBacked. (2024). TRex Bio — Funding & Investors. Retrieved June 14, 2026, from https://www.vcbacked.co/company/trex-bio

Wikipedia (cite web)

{{cite web |title=TRex Bio — Funding & Investors |url=https://www.vcbacked.co/company/trex-bio |website=VCBacked |access-date=June 14, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated November 13, 2024.